Research programme: respiratory virus inhibitor - Vybion

Drug Profile

Research programme: respiratory virus inhibitor - Vybion

Alternative Names: Respiratory virus inhibitor research programme - Viral Therapeutics; Virusorb

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vybion
  • Class Recombinant proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Influenza virus infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-virus-infections in USA (Aerosol)
  • 20 Jun 2008 Merdian Bioscience acquires recombinant proteins portfolio from Vybion
  • 14 May 2008 Vybion executes a letter of intent to sell its recombinant protein business to Meridian Bioscience
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top